×
Slow Taper off Antimalarial Is Best to Avoid Lupus Flare During Remission
https://www.medscape.com/viewarticle/941743

Nov 29th, 2020 - Slowly tapering off – or remaining on – antimalarial medications can help prevent disease flare in patients with systemic lupus erythematosus (SLE) who've achieved clinical remission for at least a year, according to a new study that was presented at the virtual annual meeting of the American College of Rheumatology. "Except in the setting of toxicity, cessation of antimalarial medication in pa...

RA Remission? Stop Methotrexate, Keep Etanercept
https://www.medscape.com/viewarticle/941555

Nov 23rd, 2020 - In patients with RA whose disease is well controlled by methotrexate combined with etanercept, withdrawal of methotrexate led to long-term outcomes that were nearly as good as continuation of combination therapy. The finding comes from the randomized, controlled SEAM-RA trial that sought to address weaknesses of previous studies. It included a long lead-in time with stringent criteria to ensure...

Gout Clinical Practice Guidelines (ACR, 2020)
https://reference.medscape.com/viewarticle/941449

Nov 23rd, 2020 - Guidelines for managing gout were published in June 2020 by the American College of Rheumatology (ACR).[1] Indications for Pharmacologic Urate-Lowering Therapy (ULT)   Initiating ULT is strongly recommended for gout patients with ≥1 subcutaneous tophi, evidence of radiographic damage (any modality) attributable to gout, or frequent gout flares (≥2 annually). Initiating ULT is conditionally reco...

Debate: After Methotrexate Failure, Is JAK Inhibitor or Biologic Next?
https://www.medscape.com/viewarticle/941432

Nov 22nd, 2020 - What is the next step in treatment after a person with rheumatoid arthritis fails to adequately respond to methotrexate — a Janus kinase (JAK) inhibitor or a biologic? That was the focus of a lively debate at the virtual annual meeting of the American College of Rheumatology. Vibeke Strand, MD, argued that JAK inhibitors offer the distinct advantage of a faster clinical response than biologics,...

Children With Kawasaki Disease Need Long-Term Surveillance for Heart Disease
https://www.medscape.com/viewarticle/940775

Nov 12th, 2020 - NEW YORK (Reuters Health) - Children with Kawasaki disease remain at an increased risk for heart problems more than 10 years after they leave the hospital, according to a new study. "The results justify additional follow up and surveillance for cardiovascular disease and cardiovascular disease risk factors, such as obesity, high blood pressure and high cholesterol, in Kawasaki disease survivors...

JIA Guideline Calls for Earlier Use of Targeted Therapies
https://www.staging.medscape.com/viewarticle/940926

Nov 12th, 2020 - A draft guideline for the management of patients with juvenile idiopathic arthritis reflects changes in therapy away from reliance on NSAIDs and glucocorticoids and toward earlier introduction of biologic disease-modifying antirheumatic drugs (DMARDs). The guideline, described in an oral session during the virtual annual meeting of the American College of Rheumatology, contains weighted recomme...

Methotrexate and Hydroxychloroquine Split on Cardiovascular Outcomes in RA
https://www.medscape.com/viewarticle/940971

Nov 12th, 2020 - No significant differences in major adverse cardiovascular events (MACE) emerged between methotrexate and hydroxychloroquine (HCQ) treatment in a comparison of adults 65 years or older with rheumatoid arthritis (RA). However, researchers reported some elevation in risk for stroke in the methotrexate group and for myocardial infarction (MI) and heart failure in the HCQ group. The primary outcome...

Sjögren's Symptom Clusters May Identify Treatment Options
https://www.medscape.com/viewarticle/940960

Nov 12th, 2020 - Patients with Sjögren's syndrome can be categorized into four distinct symptom clusters — independent of age, sex, and some disease manifestations — that may both improve symptom relief and aid in the development of targeted therapies, investigators reported. Analysis of data from a survey conducted by the Sjögren's Foundation identified four symptom clusters based on the grouping of five commo...

JIA Guideline Calls for Earlier Use of Targeted Therapies
https://www.medscape.com/viewarticle/940926

Nov 12th, 2020 - A draft guideline for the management of patients with juvenile idiopathic arthritis reflects changes in therapy away from reliance on NSAIDs and glucocorticoids and toward earlier introduction of biologic disease-modifying antirheumatic drugs (DMARDs). The guideline, described in an oral session during the virtual annual meeting of the American College of Rheumatology, contains weighted recomme...

https://www.the-rheumatologist.org/article/diversity-from-concepts-to-outcomes/
Diversity: From Concepts to Outcomes
The Rheumatologist; Bernstein S.

Nov 11th, 2020 - In 2020, terms like unconscious bias, diversity and inclusivity are buzzwords in rheumatology as well as throughout American society. The COVID-19 pandemic revealed stark disparities in healthcare outcomes for rheumatic disease patients of racial and ethnic minorities, including new research that shows Black and Latinx patients have a higher risk of hospitalization and threefold increased odds ...

PROs: Which Are Important to Patients and How Successfully Are They Integrated Into Clinical Care?
https://www.ajmc.com/view/pros-which-are-important-to-patients-and-how-successfully-are-they-integrated-into-clinical-care
The American Journal of Managed Care; Joszt L.

Nov 11th, 2020 - Although patient-reported outcomes (PROs) are increasingly being used to understand treatment effectiveness, there is still a lot unknown about what measures patients find most important. Two abstracts presented at the American College of Rheumatology’s annual meeting evaluated PROs in rheumatology and how PRO measures can be used in clinical care.

ACR Convergence 2020: Progress Toward COVID-19 Vaccines
https://www.the-rheumatologist.org/article/acr-convergence-2020-progress-toward-covid-19-vaccines/
The Rheumatologist; Hickman RJ.

Nov 10th, 2020 - A scientific session on Sunday, Nov. 8, focused on vaccine prospects in COVID-19. Dan Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and the William Bosworth Castle Professor of Medicine at Harvard Medical School in Boston, shared his insights about vaccine development across the field, reported on data concerning his lab’s con...

Inaugural ACR Distinguished Global Public Health Award Presented to Dr. Fauci
https://www.the-rheumatologist.org/article/inaugural-acr-distinguished-global-public-health-award-presented-to-dr-fauci/
The Rheumatologist; Bernstein S.

Nov 10th, 2020 - At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, ACR President Ellen M. Gravallese, MD, chief of the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital, Boston, presented the inaugural ACR Distinguished Global Public Health Award to Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), an ACR Master an...

'Reassuring' Data on Cardiac Toxicity With Hydroxychloroquine in RA, Lupus
https://www.staging.medscape.com/viewarticle/940635

Nov 9th, 2020 - NEW YORK (Reuters Health) - Hydroxychloroquine has no significant impact on heart rhythm in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), according to two studies featured at a press briefing at ACR Convergence, the 2020 annual virtual meeting of the American College of Rheumatology. "Our findings really do reinforce the fact that hydroxychloroquine is a safe an...

Treatment Sequence With Romosozumab Influences Osteoporosis Outcomes
https://www.staging.medscape.com/viewarticle/940675

Nov 9th, 2020 - Timing is everything when it comes to the use of the anabolic agent romosozumab (Evenity) for the treatment of advanced osteoporosis, a review of clinical trials suggests. In four studies with treatment sequences in which romosozumab was administered either before or following the use of an antiresorptive agent, initial treatment with 1 year of romosozumab produced substantial bone mineral dens...

'Reassuring' Data on Cardiac Toxicity With Hydroxychloroquine in RA, Lupus
https://www.medscape.com/viewarticle/940635

Nov 9th, 2020 - NEW YORK (Reuters Health) - Hydroxychloroquine has no significant impact on heart rhythm in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), according to two studies featured at a press briefing at ACR Convergence, the 2020 annual virtual meeting of the American College of Rheumatology. "Our findings really do reinforce the fact that hydroxychloroquine is a safe an...

COVID-19 antimalarial shortages affected rheumatology patients’ physical, mental health
https://www.healio.com/news/rheumatology/20201107/covid19-antimalarial-shortages-affected-rheumatology-patients-physical-mental-health

Nov 8th, 2020 - Antimalarial drug shortages due to COVID-19 affected more rheumatology patients in African and East Asian regions than those in the Americas and Europe, noted data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey.

Comparative Performances of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes
https://www.rheumatologyadvisor.com/home/conference-highlights/acr-convergence-2020/comparative-performance-of-sglt2-inhibitors-in-reducing-gout-in-t2d/

Nov 8th, 2020 - Among patients with type 2 diabetes (T2D), sodium-glucose cotransporter-2 (SGLT2) inhibitors dapagliflozin and empagliflozin vs canagliflozin show greater benefit in reducing gout, according to research results presented at the American College of Rheumatology (ACR) Convergence 2020, held virtually from November 5 to 9, 2020.

Under Pressure: An Update on Pulmonary Hypertension
https://www.the-rheumatologist.org/article/under-pressure-an-update-on-pulmonary-hypertension/
The Rheumatologist; Liebowitz J.

Nov 8th, 2020 - In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George Washington School of Medicine &...

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
https://www.the-rheumatologist.org/article/acr-convergence-2020-study-data-for-lupus-rheumatoid-arthritis/
The Rheumatologist; Hickman RJ.

Nov 8th, 2020 - At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate.